- Home
- LDI vs WVE Comparison
LDI vs WVE Comparison
Compare LDI & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- WVE
- Stock Information
- Founded
- LDI 2010
- WVE 2012
- Country
- LDI United States
- WVE Singapore
- Employees
- LDI N/A
- WVE N/A
- Industry
- LDI Finance: Consumer Services
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- LDI Finance
- WVE Health Care
- Exchange
- LDI Nasdaq
- WVE Nasdaq
- Market Cap
- LDI 954.8M
- WVE 915.6M
- IPO Year
- LDI 2021
- WVE 2015
- Fundamental
- Price
- LDI $2.98
- WVE $7.89
- Analyst Decision
- LDI Sell
- WVE Strong Buy
- Analyst Count
- LDI 3
- WVE 16
- Target Price
- LDI $2.85
- WVE $20.19
- AVG Volume (30 Days)
- LDI 11.5M
- WVE 2.1M
- Earning Date
- LDI 11-04-2025
- WVE 11-11-2025
- Dividend Yield
- LDI N/A
- WVE N/A
- EPS Growth
- LDI N/A
- WVE N/A
- EPS
- LDI N/A
- WVE N/A
- Revenue
- LDI $1,124,074,000.00
- WVE $93,946,000.00
- Revenue This Year
- LDI $19.82
- WVE N/A
- Revenue Next Year
- LDI $17.78
- WVE $6.85
- P/E Ratio
- LDI N/A
- WVE N/A
- Revenue Growth
- LDI 27.06
- WVE N/A
- 52 Week Low
- LDI $1.01
- WVE $5.28
- 52 Week High
- LDI $5.05
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- LDI 50.42
- WVE 53.95
- Support Level
- LDI $2.83
- WVE $6.91
- Resistance Level
- LDI $3.43
- WVE $8.31
- Average True Range (ATR)
- LDI 0.26
- WVE 0.44
- MACD
- LDI -0.08
- WVE 0.16
- Stochastic Oscillator
- LDI 37.06
- WVE 73.99
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.